These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 12360747

  • 1. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP.
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [Abstract] [Full Text] [Related]

  • 2. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
    Germain DP.
    J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
    [Abstract] [Full Text] [Related]

  • 3. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S, Lehn P.
    J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
    [Abstract] [Full Text] [Related]

  • 4. [Fabry's disease; towards a treatment].
    Linthorst GE, Hollak CE, Bosman DK, Heymans HS, Aerts JM.
    Ned Tijdschr Geneeskd; 2000 Dec 09; 144(50):2391-5. PubMed ID: 11145093
    [Abstract] [Full Text] [Related]

  • 5. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M, Wu IH, Zhao H, Ziegler RJ, Tousignant JD, Desnick RJ, Scheule RK, Cheng SH, Yew NS.
    J Gene Med; 2004 Jan 09; 6(1):85-92. PubMed ID: 14716680
    [Abstract] [Full Text] [Related]

  • 6. [Current management of Fabry disease].
    Cochat P, Liutkus A, Dubourg L, Levade T.
    Nephrol Ther; 2006 Jan 09; 2 Suppl 2():S167-71. PubMed ID: 17373218
    [Abstract] [Full Text] [Related]

  • 7. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ, Astrin KH, Bishop DF.
    Adv Nephrol Necker Hosp; 1989 Jan 09; 18():113-27. PubMed ID: 2564247
    [Abstract] [Full Text] [Related]

  • 8. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ, Banikazemi M.
    Nephrol Ther; 2006 Jan 09; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [Abstract] [Full Text] [Related]

  • 9. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
    Naganawa Y, Ohsugi K, Kase R, Date I, Sakuraba H, Sakuragawa N.
    Cell Transplant; 2002 Jan 09; 11(4):325-9. PubMed ID: 12162373
    [Abstract] [Full Text] [Related]

  • 10. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
    Fan JQ, Ishii S, Asano N, Suzuki Y.
    Nat Med; 1999 Jan 09; 5(1):112-5. PubMed ID: 9883849
    [Abstract] [Full Text] [Related]

  • 11. Preselective gene therapy for Fabry disease.
    Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T, Deans R, Howard BH, Malech HL, Brady RO, Medin JA.
    Proc Natl Acad Sci U S A; 2001 Mar 13; 98(6):3428-33. PubMed ID: 11248095
    [Abstract] [Full Text] [Related]

  • 12. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R, Olea T.
    Nefrologia; 2002 Mar 13; 22(6):540-6. PubMed ID: 12516287
    [Abstract] [Full Text] [Related]

  • 13. Fabry disease: recent advances in enzyme replacement therapy.
    Germain DP.
    Expert Opin Investig Drugs; 2002 Oct 13; 11(10):1467-76. PubMed ID: 12387706
    [Abstract] [Full Text] [Related]

  • 14. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
    Mignani R, Feriozzi S, Carraro G, Martinelli F, Cianciaruso B.
    G Ital Nefrol; 2009 Oct 13; 26(5):577-84. PubMed ID: 19802803
    [Abstract] [Full Text] [Related]

  • 15. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
    Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T.
    Proc Natl Acad Sci U S A; 2002 Oct 15; 99(21):13777-82. PubMed ID: 12370426
    [Abstract] [Full Text] [Related]

  • 16. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
    Ohsugi K, Kobayashi K, Itoh K, Sakuraba H, Sakuragawa N.
    J Hum Genet; 2000 Oct 15; 45(1):1-5. PubMed ID: 10697955
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
    Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P.
    Proc Natl Acad Sci U S A; 2001 Feb 27; 98(5):2676-81. PubMed ID: 11226298
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I, Tuttolomondo A, Di Chiara T, Miceli S, Vogiatzis D, Corpora F, Pinto A.
    Curr Gene Ther; 2018 Feb 27; 18(2):96-106. PubMed ID: 29618309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.